Porcilis Begonia - Product Overview
Porcilis Begonia
Porcilis Begonia is based on the virus strain NIA-3 and has been made tk and gE negative (tk-, gE-). The resulting vaccine strain is genetically stable and does not cause latency in pigs. The gE deletion allows field infections to be differentiated from vaccination responses. Dissolving the vaccine in Diluvac Forte enhances the immune response. Some other key information (trademarks - accreditations etc.) would go here if wanted.


More Info on Porcilis


Porcilis Begonia - Data Sheet
Product Class
Vaccines
Target Species
Pigs
Description
It contains the toxoid of Pasteurella multocida dermo-necrotic toxin (DNT) and inactivated Bordetella bronchiseptica cells, in a water-in-oil adjuvant. Protection is transferred from the vaccinated sow or gilt to the piglets by maternally derived antibodies (MDA) through the intake of colostrum.
Composition
Each dose contains active component 105. 5 TCID50 of Aujeszky�s disease virus strain Begonia. The vaccine is dissolved in Diluvac Forte.
Formulation
The vaccine is a freeze-dried live attenuated vaccine. It must be reconstituted before use.
Indications
Active immunisation of pigs against Aujeszky�s disease virus infections (Pseudorabies).
Vaccination
Fattening pigs: When maternally derived antibodies (MDA) are not present, piglets can be vaccinated as early as 1 week of age without any problems. Immunity after a single injection will last the whole of the fattening period, or at least until 6 months of age. When MDA are present, piglets can be given a single dose at 14 weeks of age. Protection will last the whole of the fattening period. When there is a risk of early infection, pigs carrying varying levels of MDA can be vaccinated from 10 weeks of age onwards and should be re-vaccinated at 14 weeks of age, but no earlier than 4 weeks after the first dose.

Breeding pigs: Basic vaccination: as for fattening pigs.

Repeat vaccinations: Eradication: at 4 month intervals, three times per year as a herd vaccination programme. Control: end of each pregnancy, not later than 2 weeks before farrowing.
Method of administration
2 ml of the reconstituted product by intramuscular injection.
Withholding period
Nil
Presentation
Vaccine: Glass vials containing a freeze dried plug, equivalent to 10, 25, 50 or 100 doses.

Diluent: Glass bottles containing 20, 50, 100 or 200 ml of diluent.
Storage
Vaccine: Store at a temperature of 2-8�C. Protect from light. Do not freeze.

Diluent: Store at room temperature.
Contra-indications
Young animals with maternal antibodies may need re-vaccination (see vaccination scheme). Should not be used in dogs. There have been occasional reports of unwanted reactions to vaccination with Porcilis Begonia. These side-effects are likely to be closely related to certain specific conditions prevailing on the farm and are normally of a transient nature.
Further information
This strain synthesises neither thymidine kinase (tk-) nor the glycoprotein E (gE-). Animals immunised with this vaccine can be distinguished serologically (gE based test) from animals infected with field virus, making it essential component in eradication programmes. The use of Diluvac Forte results in higher antibody titres, improved protection and reduced AD virus excretion, compared to using traditional aqueous adjuvants.
Precautions



Publication date: 1st June 2005